• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Catheter Precision Inc.

    6/13/25 6:24:34 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    424B5 1 vtak20250612_424b5.htm FORM 424B5 vtak20250612_424b5.htm

     

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-284217

     

    PROSPECTUS SUPPLEMENT

    To Prospectus Supplement dated May 19, 2025

    (To Prospectus dated January 22, 2025)

     

     

     

    logo.jpg

     

    Up to $1,895,679

     

    Common Stock

     

     

    This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3 (333-284217), (collectively, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the At The Market Offering Agreement, dated May 19, 2025 (the “Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) as sales agent. During the twelve calendar months prior to, and including, the date hereof, we have sold an aggregate of 2,884,909 shares of our common stock for aggregate gross proceeds of approximately $1,290,116 through Ladenburg under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto.

     

    As of the date of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $9,557,387, which was calculated based on 15,928,979 shares of our outstanding common stock held by non-affiliates and a price of $0.60 per share, the closing price of our common stock on June 11, 2025, which is the highest closing sale price of our common stock on the NYSE American within the prior 60 days. As of the date of this Prospectus Supplement, we have sold securities with an aggregate market value of approximately $1,290,116 pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12 calendar month period so long as our public float remains below $75.0 million.

     

    We are filing this Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell from and after the date hereof, and to specify the value of common stock we would be permitted to sell in any 12 calendar month period under General Instruction I.B.6. We may currently only offer and sell shares of our common stock having an aggregate offering price of up to $1,895,679 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement, and as a result of the limitations set forth in General Instruction I.B.6. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales. 

     

    Our common stock trades on the NYSE American under the symbol “VTAK.” On June 12, 2025, the last reported sale price of our common stock on the NYSE American was $0.4232 per share. 

     

    Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page S-3 of the ATM Prospectus and contained in the documents incorporated by reference into this prospectus supplement and the ATM Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    Ladenburg Thalmann & Co. Inc.

     


     

    Prospectus Supplement dated June 13, 2025

     

     

     

     
    Get the next $VTAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

      SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

      11/14/24 5:12:56 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

      SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

      11/13/24 11:14:58 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

      SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

      10/30/24 5:26:20 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Financials

    Live finance-specific insights

    See more
    • Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

      FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

      5/14/25 4:30:00 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

      FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

      3/28/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces Third Quarter Update and Financial Results

      FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i

      11/13/24 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VTAK
    SEC Filings

    See more
    • Catheter Precision, Inc. Comments on Recent Market Activity

      FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs. CONTACTS: At the CompanyDavid [email protected] # # #

      6/12/25 2:14:04 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Receives CE Mark for LockeT

      Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device. Receipt of the CE Mark indicates compliance with European Union (EU) regulations, specifically health, safety, and environmental protection standards. With this approval, LockeT is now eligible to be placed in markets within the EU and additional countries such as the UK, Switzerl

      5/27/25 9:58:25 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

      FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

      5/14/25 4:30:00 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B5 filed by Catheter Precision Inc.

      424B5 - Catheter Precision, Inc. (0001716621) (Filer)

      6/13/25 6:24:34 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      6/13/25 6:23:06 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Catheter Precision Inc.

      DEFA14A - Catheter Precision, Inc. (0001716621) (Filer)

      6/9/25 7:53:21 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Anderson Philip J

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      3/3/25 5:17:48 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Director Colombatto Martin J sold $1 worth of shares (3 units at $0.40) (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/31/25 4:39:51 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/31/25 4:39:10 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Catheter Precision, Inc. Announces New Chief Financial Officer

      FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

      1/7/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

      FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

      1/22/24 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care